Researchers from Sanford Burnham Prebys and the Chinese University of Hong Kong have developed a computational approach to predict whether a person with type 2 diabetes will develop kidney disease. The findings could help doctors prevent or better manage kidney disease in people with type 2 diabetes.
One of the biggest goals of immunotherapy is to reverse T cell exhaustion to boost the immune system’s ability to destroy cancerous cells. Researchers at Sanford Burnham Prebys studying melanoma have found a new way to make this happen.
Researchers led by Sanford Burnham Prebys assistant professor Lukas Chavez, Ph.D., are leveraging the latest technology to take a never-before-seen look at ependymoma, one of the deadliest pediatric brain tumors. By visualizing how the genome is organized and arranged within tumor cells, they were able to reveal genes in tumors that may be future targets for therapy. The results appear in Nature Communications.
With the help of a new grant from the U.S. Department of Defense for more than $1.7 million, Associate Professor Charles Spruck, Ph.D., will advance an innovative therapeutic approach for metastatic prostate cancer. Known as viral mimicry, the approach tricks the body into thinking that it has a viral infection, stimulating an immune response that can help the body fight cancer.
Sanford Burnham Prebys researchers have identified a group of proteins that could be the secret to cellular reprogramming, an emerging approach in regenerative medicine in which scientists transform cells to repair damaged or injured body tissues.
Cosimo Commisso, Ph.D., and Susanne Heynen-Genel, Ph.D., have received a grant from the National Cancer Institute (NCI) to advance a new treatment approach for pancreatic cancer.
Sanford Burnham Prebys today announced that Professor Nicholas Cosford, Ph.D., will join the Institute’s Board of Trustees.
A top rating on Charity Navigator means Sanford Burnham Prebys is among the most trusted charities nationwide in terms of financial health and accountability.
For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme. The findings could help address the growing threat of prostate cancer resistance and could also lead to improved treatments for other cancers.
Research has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug. The study, published in the Proceedings of the National Academy of Sciences, has the potential to transform treatment for this rare disease and may also have implications for more common diseases.
Lukas Chavez, Ph.D., has joined Sanford Burnham Prebys as an assistant professor in the Tumor Initiation and Maintenance Program to continue his research on chromatin and gene regulation in childhood brain cancers.
A newly discovered link between protein misfolding and liver cancer could help improve gene therapy for hemophilia.
A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity. DS-1211 is a potential first-in-class small molecule developed through a research collaboration between Daiichi Sankyo and Sanford Burnham Prebys.
Molecular biologist Yu Xin (Will) Wang, Ph.D., has joined Sanford Burnham Prebys as an assistant professor in the Development, Aging, and Regeneration Program to uncover the ways muscle, nerve and immune cells work together to overcome disease.
Sanford Burnham Prebys professor Randal J. Kaufman, Ph.D. was included on Clarivate’s 2022 Highly Cited Researchers list, a global ranking of influential researchers based on the number of times their work has been cited in peer-reviewed publication over the last decade.
For the third time, Sanford Burnham Prebys has been selected by the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., supporting the NCI Experimental Therapeutics (NExT) Program as a Center for the Chemical Biology Consortium (CBC).
Two faculty members from Sanford Burnham Prebys have been awarded grants from the American Cancer Society (ACS), the largest not-for-profit funding body for scientists studying cancer. Associate Professor Cosimo Commisso, Ph.D., and Assistant Professor Svasti Haricharan, Ph.D., each received competitive awards to advance their work on difficult-to-treat cancers.
The Flow Cytometry Core at Sanford Burnham Prebys is getting a new piece of state-of-the-art research equipment, thanks to a grant from the National Institutes of Health.
Sanford Burnham Prebys has partnered with more than 50 cancer organizations to issue a call to action urging individuals, providers and insurers to increase access to and utilization of low-dose computed tomography (CT) scans for those at high risk for lung cancer.
Distinguished Professor Emeritus Erkki Ruoslahti, M.D., Ph.D., has been announced as one of three winners of the Albert Lasker Basic Medical Research Award, the most prestigious American award for biomedical research, for his transformational research leading to the discovery of the cell adhesion receptors now known as integrins.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
